SUPPLEMENT

Q2 2026 — Other Financial Disclosures

Q2 2026PDF · 17 pages620 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 7
Table 4: Condensed Consolidated Statement of Earnings - QTD 8
Table 5: Condensed Consolidated Statement of Earnings - YTD 9
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11
Table 8: Non-GAAP Adjusted Net Earnings 12
Table 9: Non-GAAP P&L by Segment Reconciliation 2026 - QTD 13
Table 10: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 14
Table 11: Non-GAAP P&L by Segment Reconciliation 2026 - YTD 15
Table 12: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 16
Second Quarter 2026
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operations Currency 2026 2025 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 9,979	$ 9,161 8.9 % 8.9 - 18,850	$ 17,253 9.3 % 9.3 -
International 6,405 6,041 6.0 3.6 2.4 12,960 11,822 9.6 3.9 5.7
16,384 15,202 7.8 6.8 1.0 31,810 29,075 9.4 7.1 2.3
MedTech
U.S. 4,554 4,383 3.9 3.9 - 9,013 8,596 4.8 4.8 -
International 4,372 4,158 5.2 3.2 2.0 8,549 7,965 7.3 3.2 4.1
8,926 8,541 4.5 3.6 0.9 17,562 16,561 6.0 4.1 1.9
U.S. 14,533 13,544 7.3 7.3 - 27,863 25,849 7.8 7.8 -
International 10,777 10,199 5.7 3.4 2.3 21,509 19,787 8.7 3.6 5.1
Worldwide 25,310	$ 23,743 6.6 % 5.6 1.0 49,372	$ 45,636 8.2 % 6.0 2.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2026 2025 Total Operational Currency 2026 2025 Total Operational Currency
Sales to customers by
geographic area
U.S. 14,533	$ 13,544 7.3 % 7.3 - 27,863	$ 25,849 7.8 % 7.8 -
Europe 5,726 5,387 6.3 3.3 3.0 11,574 10,497 10.3 3.0 7.3
Western Hemisphere excluding U.S. 1,309 1,206 8.5 2.7 5.8 2,602 2,373 9.6 2.6 7.0
Asia-Pacific, Africa 3,742 3,606 3.8 3.9 (0.1) 7,333 6,917 6.0 4.9 1.1
International 10,777 10,199 5.7 3.4 2.3 21,509 19,787 8.7 3.6 5.1
Worldwide 25,310	$ 23,743 6.6 % 5.6 1.0 49,372	$ 45,636 8.2 % 6.0 2.2
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
SECOND QUARTER SIX MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
ONCOLOGY
US 4,069	$ 3,385 20.3% 20.3% - 7,684	$ 6,398 20.1% 20.1% -
Intl 3,337 2,928 14.0% 11.2% 2.8% 6,695 5,592 19.7% 13.2% 6.5%
WW 7,406 6,312 17.3% 16.1% 1.2% 14,379 11,990 19.9% 16.9% 3.0%
DARZALEX
US 2,435 2,017 20.7% 20.7% - 4,643 3,846 20.7% 20.7% -
Intl 1,772 1,521 16.4% 13.5% 2.9% 3,528 2,930 20.4% 13.7% 6.7%
WW 4,207 3,539 18.9% 17.6% 1.3% 8,171 6,776 20.6% 17.7% 2.9%
CARVYKTI
US 472 358 31.7% 31.7% - 905 676 33.8% 33.8% -
Intl 185 81 * * * 349 132 * * *
WW 657 439 49.4% 47.7% 1.7% 1,254 808 55.1% 52.1% 3.0%
TECVAYLI
US 186 114 63.9% 63.9% - 313 219 43.1% 43.1% -
Intl 74 52 40.7% 39.2% 1.5% 148 98 51.1% 45.2% 5.9%
WW 260 166 56.5% 56.1% 0.4% 462 317 45.5% 43.7% 1.8%
TALVEY
US 112 82 36.2% 36.2% - 213 150 41.7% 41.7% -
Intl 62 24 * * * 113 42 * * *
WW 174 106 63.3% 62.6% 0.7% 326 192 69.3% 67.2% 2.1%
RYBREVANT / LAZCLUZE
US 190 139 36.8% 36.8% - 365 252 45.0% 45.0% -
Intl 99 41 * * * 181 69 * * *
WW 289 179 60.8% 61.6% (0.8)% 546 320 70.4% 69.9% 0.5%
ERLEADA
US 396 378 4.7% 4.7% - 738 670 10.2% 10.2% -
Intl 599 530 12.9% 9.7% 3.2% 1,206 1,009 19.4% 12.5% 6.9%
WW 995 908 9.5% 7.6% 1.9% 1,944 1,679 15.8% 11.6% 4.2%
IMBRUVICA
US 149 239 (37.6)% (37.6)% - 292 474 (38.4)% (38.4)% -
Intl 449 496 (9.5)% (11.8)% 2.3% 966 970 (0.4)% (6.7)% 6.3%
WW 599 735 (18.6)% (20.2)% 1.6% 1,259 1,444 (12.9)% (17.1)% 4.2%
OTHER ONCOLOGY (3)
US 131 56 * * - 216 110 94.5% 94.5% -
Intl 97 181 (46.5)% (45.7)% (0.8)% 203 341 (40.5)% (41.3)% 0.8%
WW 226 238 (4.6)% (3.9)% (0.7)% 418 452 (7.4)% (8.0)% 0.6%
See footnotes at end of schedule
% Change	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
IMMUNOLOGY
US 2,372	$ 2,505 (5.3)% (5.3)% - 4,227	$ 4,701 (10.1)% (10.1)% -
Intl 1,473 1,489 (1.0)% (3.5)% 2.5% 2,997 2,999 (0.1)% (5.0)% 4.9%
WW 3,844 3,993 (3.7)% (4.6)% 0.9% 7,224 7,700 (6.2)% (8.1)% 1.9%
TREMFYA
US 1,465 796 84.2% 84.2% - 2,507 1,395 79.7% 79.7% -
Intl 581 391 48.7% 44.2% 4.5% 1,147 747 53.6% 45.5% 8.1%
WW 2,046 1,186 72.5% 71.0% 1.5% 3,654 2,142 70.6% 67.8% 2.8%
SIMPONI / SIMPONI ARIA
US 260 305 (14.6)% (14.6)% - 529 597 (11.2)% (11.2)% -
Intl 358 387 (7.3)% (9.5)% 2.2% 736 753 (2.3)% (6.9)% 4.6%
WW 618 690 (10.5)% (11.7)% 1.2% 1,265 1,349 (6.2)% (8.8)% 2.6%
REMICADE
US 215 283 (24.1)% (24.1)% - 484 597 (19.0)% (19.0)% -
US Exports (4) 10 34 (71.0)% (71.0)% - 28 44 (37.1)% (37.1)% -
Intl 112 138 (18.4)% (20.5)% 2.1% 248 281 (11.5)% (15.4)% 3.9%
WW 338 455 (25.8)% (26.4)% 0.6% 760 922 (17.6)% (18.7)% 1.1%
STELARA
US 336 1,078 (68.8)% (68.8)% - 556 2,059 (73.0)% (73.0)% -
Intl 404 575 (29.7)% (31.1)% 1.4% 839 1,219 (31.1)% (34.6)% 3.5%
WW 740 1,653 (55.2)% (55.7)% 0.5% 1,396 3,278 (57.4)% (58.7)% 1.3%
OTHER IMMUNOLOGY
US 85 8 * * - 123 9 * * -
Intl 18 0 * * * 27 0 * * *
WW 104 8 * * * 150 9 * * *
NEUROSCIENCE
US 1,659 1,377 20.5% 20.5% - 3,153 2,345 34.5% 34.5% -
Intl 678 674 0.6% (1.1)% 1.7% 1,359 1,353 0.4% (3.7)% 4.1%
WW 2,337 2,051 14.0% 13.4% 0.6% 4,512 3,698 22.0% 20.5% 1.5%
SPRAVATO
US 514 366 40.7% 40.7% - 920 642 43.4% 43.4% -
Intl 70 50 41.2% 34.7% 6.5% 131 93 41.8% 31.9% 9.9%
WW 584 414 40.8% 40.0% 0.8% 1,052 734 43.2% 42.0% 1.2%
CAPLYTA (5)
US 361 211 70.9% 70.9% - 631 211 * * -
Intl - - - - - - - - - -
WW 361 211 70.9% 70.9% - 631 211 * * -
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 738 732 0.8% 0.8% - 1,496 1,357 10.2% 10.2% -
Intl 278 260 6.6% 5.1% 1.5% 558 537 3.7% (0.1)% 3.8%
WW 1,015 992 2.3% 1.9% 0.4% 2,053 1,895 8.4% 7.3% 1.1%
CONCERTA / Methylphenidate
US 12 24 (48.6)% (48.6)% - 34 62 (45.5)% (45.5)% -
Intl 133 139 (4.2)% (4.8)% 0.6% 248 249 (0.4)% (3.0)% 2.6%
WW 146 164 (10.8)% (11.3)% 0.5% 282 312 (9.5)% (11.5)% 2.0%
OTHER NEUROSCIENCE
US 34 45 (22.9)% (22.9)% - 72 73 (1.1)% (1.1)% -
Intl 198 226 (12.3)% (13.7)% 1.4% 422 474 (10.9)% (15.1)% 4.2%
WW 232 270 (14.0)% (15.2)% 1.2% 494 547 (9.6)% (13.2)% 3.6%
See footnotes at end of schedule
% Change	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
PULMONARY HYPERTENSION (PH)
US 814	$ 799 1.8% 1.8% - 1,645	$ 1,543 6.5% 6.5% -
Intl 329 314 4.9% 3.4% 1.5% 633 595 6.4% 2.3% 4.1%
WW 1,143 1,113 2.6% 2.2% 0.4% 2,278 2,138 6.5% 5.4% 1.1%
UPTRAVI
US 386 382 1.0% 1.0% - 771 747 3.2% 3.2% -
Intl 108 94 15.0% 10.1% 4.9% 206 180 14.7% 7.7% 7.0%
WW 494 476 3.8% 2.8% 1.0% 977 927 5.4% 4.0% 1.4%
OPSUMIT / OPSYNVI
US 416 403 3.2% 3.2% - 849 766 10.9% 10.9% -
Intl 187 180 3.9% 3.6% 0.3% 359 339 6.1% 2.7% 3.4%
WW 602 582 3.4% 3.3% 0.1% 1,208 1,104 9.4% 8.4% 1.0%
OTHER PULMONARY HYPERTENSION
US 13 16 (16.9)% (16.9)% - 25 31 (19.0)% (19.0)% -
Intl 34 40 (14.3)% (12.7)% (1.6)% 68 77 (11.5)% (12.3)% 0.8%
WW 47 55 (15.0)% (13.9)% (1.1)% 93 107 (13.6)% (14.2)% 0.6%
INFECTIOUS DISEASES (ID)
US 300 320 (6.3)% (6.3)% - 642 635 1.1% 1.1% -
Intl 463 484 (4.1)% (6.2)% 2.1% 1,010 971 4.1% (2.5)% 6.6%
WW 763 803 (5.0)% (6.3)% 1.3% 1,652 1,605 2.9% (1.1)% 4.0%
EDURANT / rilpivirine
US 3 6 (49.6)% (49.6)% - 10 14 (29.3)% (29.3)% -
Intl 347 354 (1.9)% (3.8)% 1.9% 749 704 6.4% (0.3)% 6.7%
WW 350 360 (2.7)% (4.6)% 1.9% 759 718 5.7% (0.9)% 6.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 296 312 (5.1)% (5.1)% - 630 617 2.1% 2.1% -
Intl 76 85 (10.4)% (12.8)% 2.4% 185 183 1.2% (5.6)% 6.8%
WW 372 396 (6.3)% (6.8)% 0.5% 815 799 1.9% 0.4% 1.5%
OTHER INFECTIOUS DISEASES
US 1 2 (47.9)% (47.9)% - 2 4 (51.6)% (51.6)% -
Intl 40 45 (9.6)% (12.8)% 3.2% 76 84 (9.0)% (13.7)% 4.7%
WW 41 47 (11.6)% (14.6)% 3.0% 78 88 (11.1)% (15.5)% 4.4%
CARDIOVASCULAR / METABOLISM / OTHER (CVM)
US 765 776 (1.3)% (1.3)% - 1,499 1,631 (8.1)% (8.1)% -
Intl 124 154 (19.4)% (21.5)% 2.1% 266 312 (14.8)% (19.5)% 4.7%
WW 889 930 (4.3)% (4.7)% 0.4% 1,765 1,943 (9.2)% (9.9)% 0.7%
XARELTO
US 664 621 7.1% 7.1% - 1,306 1,311 (0.3)% (0.3)% -
Intl - - - - - - - - - -
WW 664 621 7.1% 7.1% - 1,306 1,311 (0.3)% (0.3)% -
OTHER
US 101 155 (35.0)% (35.0)% - 192 320 (39.9)% (39.9)% -
Intl 124 154 (19.4)% (21.5)% 2.1% 266 312 (14.8)% (19.5)% 4.7%
WW 225 309 (27.2)% (28.3)% 1.1% 458 632 (27.5)% (29.8)% 2.3%
TOTAL PH, ID, CVM
US 1,878 1,895 (0.9)% (0.9)% - 3,785 3,809 (0.6)% (0.6)% -
Intl 916 952 (3.6)% (5.5)% 1.9% 1,909 1,878 1.7% (3.8)% 5.5%
WW 2,795 2,846 (1.8)% (2.4)% 0.6% 5,694 5,686 0.1% (1.7)% 1.8%
TOTAL INNOVATIVE MEDICINE
US 9,979 9,161 8.9% 8.9% - 18,850 17,253 9.3% 9.3% -
Intl 6,405 6,041 6.0% 3.6% 2.4% 12,960 11,822 9.6% 3.9% 5.7%
WW 16,384	$ 15,202 7.8% 6.8% 1.0% 31,810	$ 29,075 9.4% 7.1% 2.3%
See footnotes at end of schedule
% Change	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
MEDTECH SEGMENT (2) 2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,426	$ 1,364 4.5% 4.5% - 2,825	$ 2,625 7.6% 7.6% -
Intl 978 948 3.2% 1.1% 2.1% 1,956 1,790 9.3% 5.2% 4.1%
WW 2,404 2,313 4.0% 3.1% 0.9% 4,781 4,416 8.3% 6.6% 1.7%
ELECTROPHYSIOLOGY
US 783 741 5.8% 5.8% - 1,519 1,425 6.6% 6.6% -
Intl 749 728 2.9% 0.4% 2.5% 1,502 1,366 10.0% 5.6% 4.4%
WW 1,533 1,468 4.4% 3.1% 1.3% 3,022 2,791 8.3% 6.2% 2.1%
ABIOMED
US 342 360 (4.8)% (4.8)% - 731 699 4.6% 4.6% -
Intl 97 89 9.5% 9.2% 0.3% 197 170 16.1% 11.4% 4.7%
WW 440 448 (2.0)% (2.0)% 0.0% 928 868 6.8% 5.9% 0.9%
SHOCKWAVE
US 268 233 14.6% 14.6% - 510 439 16.1% 16.1% -
Intl 67 58 14.5% 15.4% (0.9)% 130 110 17.7% 17.2% 0.5%
WW 335 292 14.6% 14.7% (0.1)% 640 550 16.4% 16.3% 0.1%
OTHER CARDIOVASCULAR
US 33 31 5.5% 5.5% - 65 63 3.1% 3.1% -
Intl 65 72 (10.5)% (13.2)% 2.7% 127 144 (11.9)% (15.3)% 3.4%
WW 98 104 (5.7)% (7.5)% 1.8% 192 207 (7.4)% (9.7)% 2.3%
SURGERY
US 1,094 1,043 5.0% 5.0% - 2,140 2,045 4.7% 4.7% -
Intl 1,559 1,512 3.1% 0.5% 2.6% 3,024 2,906 4.1% (0.3)% 4.4%
WW 2,653 2,555 3.9% 2.3% 1.6% 5,164 4,951 4.3% 1.8% 2.5%
ADVANCED
US 499 477 4.7% 4.7% - 976 934 4.5% 4.5% -
Intl 691 687 0.5% (1.9)% 2.4% 1,337 1,303 2.6% (1.4)% 4.0%
WW 1,189 1,164 2.2% 0.8% 1.4% 2,312 2,237 3.4% 1.0% 2.4%
GENERAL
US 596 567 5.2% 5.2% - 1,165 1,111 4.8% 4.8% -
Intl 868 825 5.3% 2.5% 2.8% 1,687 1,603 5.2% 0.7% 4.5%
WW 1,464 1,391 5.2% 3.6% 1.6% 2,852 2,714 5.1% 2.4% 2.7%
See footnotes at end of schedule
% Change	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
SECOND QUARTER SIX MONTHS
2026 2025 Reported Operational (1) Currency 2026 2025 Reported Operational (1) Currency
VISION
US 565	$ 557 1.4% 1.4% - 1,144	$ 1,123 1.9% 1.9% -
Intl 887 813 9.1% 8.5% 0.6% 1,672 1,526 9.6% 6.7% 2.9%
WW 1,451 1,369 6.0% 5.6% 0.4% 2,816 2,648 6.3% 4.6% 1.7%
CONTACT LENSES / OTHER
US 445 429 3.6% 3.6% - 913 881 3.7% 3.7% -
Intl 580 536 8.1% 7.9% 0.2% 1,081 1,003 7.7% 5.0% 2.7%
WW 1,025 965 6.1% 6.0% 0.1% 1,994 1,884 5.8% 4.4% 1.4%
SURGICAL
US 120 128 (6.0)% (6.0)% - 231 242 (4.5)% (4.5)% -
Intl 306 277 10.9% 9.6% 1.3% 591 523 13.1% 9.8% 3.3%
WW 426 403 5.6% 4.7% 0.9% 822 764 7.5% 5.3% 2.2%
ORTHOPAEDICS
US 1,470 1,420 3.5% 3.5% - 2,905 2,804 3.6% 3.6% -
Intl 948 885 7.2% 5.3% 1.9% 1,896 1,742 8.9% 3.9% 5.0%
WW 2,418 2,305 4.9% 4.2% 0.7% 4,801 4,546 5.6% 3.7% 1.9%
HIPS
US 283 271 4.6% 4.6% - 560 534 4.9% 4.9% -
Intl 158 150 5.5% 3.0% 2.5% 317 296 7.2% 1.7% 5.5%
WW 441 421 4.9% 4.0% 0.9% 877 830 5.7% 3.8% 1.9%
KNEES
US 228 226 1.1% 1.1% - 467 457 2.2% 2.2% -
Intl 182 164 11.4% 10.3% 1.1% 363 322 13.0% 8.4% 4.6%
WW 410 389 5.5% 5.0% 0.5% 830 778 6.7% 4.8% 1.9%
TRAUMA
US 536 501 6.7% 6.7% - 1,068 1,003 6.4% 6.4% -
Intl 291 267 9.2% 7.4% 1.8% 592 537 10.3% 5.2% 5.1%
WW 827 768 7.6% 6.9% 0.7% 1,660 1,540 7.8% 6.0% 1.8%
SPINE, SPORTS & OTHER
US 423 422 0.2% 0.2% - 810 810 0.0% 0.0% -
Intl 317 305 4.0% 1.9% 2.1% 624 588 6.1% 1.3% 4.8%
WW 740 727 1.8% 0.9% 0.9% 1,434 1,398 2.6% 0.6% 2.0%
TOTAL MEDTECH
US 4,554 4,383 3.9% 3.9% - 9,013 8,596 4.8% 4.8% -
Intl 4,372 4,158 5.2% 3.2% 2.0% 8,549 7,965 7.3% 3.2% 4.1%
WW 8,926	$ 8,541 4.5% 3.6% 0.9% 17,562	$ 16,561 6.0% 4.1% 1.9%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of ZYTIGA which were previously disclosed separately
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change	% Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 25,310	$ 100.0 23,743	$ 100.0 6.6
Cost of products sold 8,051 31.8 7,628 32.1 5.5
Gross Profit 17,259 68.2 16,115 67.9 7.1
Selling, marketing and administrative expenses 6,432 25.4 5,889 24.8 9.2
Research and development expense 3,653 14.4 3,516 14.8 3.9
Interest (income) expense, net 62 0.2 48 0.2
Other (income) expense, net 331 1.3 107 0.5
Restructuring 34 0.2 64 0.3
Earnings before provision for taxes on income 6,747 26.7 6,491 27.3 3.9
Provision for taxes on income 1,213 4.8 954 4.0 27.1
Net earnings 5,534	$ 21.9 5,537	$ 23.3 (0.1)
Net earnings per share (Diluted) 2.27	$ 2.29	$ (0.9)
Average shares outstanding (Diluted) 2,440.1 2,419.1
Effective tax rate 18.0 % 14.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,660	$ 34.2 8,188	$ 34.5 5.8
Net earnings 7,081	$ 28.0 6,699	$ 28.2 5.7
Net earnings per share (Diluted) 2.90	$ 2.77	$ 4.7
Effective tax rate 18.2 % 18.2 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SECOND QUARTER
2026 2025

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 49,372	$ 100.0 45,636	$ 100.0 8.2
Cost of products sold 16,157 32.7 14,985 32.8 7.8
Gross Profit 33,215 67.3 30,651 67.2 8.4
Selling, marketing and administrative expenses 12,466 25.3 11,001 24.1 13.3
Research and development expense 7,180 14.5 6,741 14.8 6.5
In-process research and development impairments 36 0.1 - -
Interest (income) expense, net 105 0.2 (80) (0.2)
Other (income) expense, net 625 1.3 (7,214) (15.8)
Restructuring 66 0.1 81 0.2
Earnings before provision for taxes on income 12,737 25.8 20,122 44.1 (36.7)
Provision for taxes on income 1,968 4.0 3,586 7.9 (45.1)
Net earnings 10,769	$ 21.8 16,536	$ 36.2 (34.9)
Net earnings per share (Diluted) 4.41	$ 6.82	$ (35.3)
Average shares outstanding (Diluted) 2,443.9 2,423.3
Effective tax rate 15.5 % 17.8 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 16,481	$ 33.4 16,199	$ 35.5 1.7
Net earnings 13,695	$ 27.7 13,405	$ 29.4 2.2
Net earnings per share (Diluted) 5.60	$ 5.53	$ 1.3
Effective tax rate 16.9 % 17.2 %
(1) See Reconciliation of Non-GAAP Financial Measures.
SIX MONTHS
2026 2025

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 7.8% 4.5% 6.6%
U.S. 8.9% 3.9% 7.3%
International 6.0% 5.2% 5.7%
WW Currency 1.0 0.9 1.0
U.S. - - -
International 2.4 2.0 2.3
WW Operational 6.8% 3.6% 5.6%
U.S. 8.9% 3.9% 7.3%
International 3.6% 3.2% 3.4%
All Other Acquisitions and Divestitures (A&D) 0.1 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.9% 3.7% 5.7%
U.S. 8.9% 4.1% 7.4%
International 3.8% 3.2% 3.5%
Adjusted Operational Sales Growth
SECOND QUARTER 2026 ACTUAL vs. 2025 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 9.4% 6.0% 8.2%
U.S. 9.3% 4.8% 7.8%
International 9.6% 7.3% 8.7%
WW Currency 2.3 1.9 2.2
U.S. - - -
International 5.7 4.1 5.1
WW Operational 7.1% 4.1% 6.0%
U.S. 9.3% 4.8% 7.8%
International 3.9% 3.2% 3.6%
Caplyta (0.9) (0.6)
U.S. (1.6) (1.0)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1
U.S. 0.0 0.2 0.1
International 0.2 0.0 0.1
WW Adjusted Operational Ex A&D 6.2% 4.2% 5.5%
U.S. 7.7% 5.0% 6.9%
International 4.1% 3.2% 3.7%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
SIX MONTHS 2026 ACTUAL vs. 2025 ACTUAL
Segments

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2026 2025 2026 2025
Net Earnings, after tax- as reported $5,534 $5,537 $10,769 $16,536
Pre-tax Adjustments
Litigation related 267 57 597 (6,909)
Intangible Asset Amortization expense 1,245 1,267 2,492 2,387
Restructuring related 1 276 79 338 134
Orthopaedics separation related 258 - 377 -
Acquisition, integration and divestiture related 80 246 176 378
(Gains)/losses on securities (213) 21 (272) 60
IPR&D impairments - - 36 -
Other - 27 - 27
Tax Adjustments
Tax impact on special item adjustments 2 (368) (321) (792) 994
Tax legislation and other tax related 2 (214) (26) (202)
Adjusted Net Earnings , after tax $7,081 $6,699 $13,695 $13,405
Average shares outstanding (Diluted) 2,440.1 2,419.1 2,443.9 2,423.3
Adjusted net earnings per share (Diluted) $2.90 $2.77 $5.60 $5.53
Operational adjusted net earnings per share (Diluted) $2.86 $5.43
Notes:
1
2
Second Quarter Six Months Ended
In the fiscal second quarter of 2026, the Company commenced a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its
optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site
and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $200 million, primarily related to asset impairments, were recorded in the fiscal second quarter of
2026.
In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and
optimize select sites across the network. Restructuring expenses of $59 million were recorded in the fiscal second quarter of 2026 ($114 million Q2 2026 YTD) and $29 million in the fiscal second
quarter of 2025 ($29 million Q2 2025 YTD) and primarily include costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and
distribution network arrangements. The restructuring expenses of $17 million in the fiscal second quarter of 2026 ($24 million Q2 2026 YTD) and $50 million in the fiscal second quarter of 2025
($105 million Q2 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 13 of 17 --

Innovative Medicine
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 4,296	$ (764) (18) (9) 3,505
Selling, marketing and admin expenses 3,130 3,130
Research and development expense 2,875 2,875
Other segment items (166) 91 (182) (54) 227 (84)
Adjusted Income Before Tax by Segment 6,249 764 (91) 200 63 (227) - - 6,958
MedTech
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 3,737	$ (481) (17) (3) 3,236
Selling, marketing and admin expenses 3,069 (17) 3,052
Research and development expense 778 (2) 776
Other segment items 165 76 (59) (37) (14) (236) (105)
Adjusted Income Before Tax by Segment 1,177 481 (76) 76 37 14 258 - 1,967
Expenses not allocated to segments
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 18	$ 18
Selling, marketing and admin expenses 233 233
Research and development expense - -
Other segment items 428 (434) 20 14
Adjusted Income Before Tax by Segment (679) - 434 - (20) - - - (265)
Johnson & Johnson Consolidated
Second Quarter
June 28, 2026
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Second Quarter
June 28, 2026
Non-GAAP
Cost of products sold 8,051	$ (1,245) (35) (9) (3) 6,759
Selling, marketing and admin expenses 6,432 (17) 6,415
Research and development expense 3,653 (2) 3,651
Other (Income) / Expense 331 (267) (207) (71) 213 (236) (237)
In-process research and development impairments - -
Interest (Income)/Expense 62 62
Restructuring 34 (34) -
Adjusted Income Before Tax 6,747 1,245 267 276 80 (213) 258 - 8,660
Provision for taxes on income 1,213 239 59 54 23 (50) 43 (2) 1,579
Net Earnings 5,534	$ 1,006 208 222 57 (163) 215 2 7,081
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 14 of 17 --

Innovative Medicine
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 3,978	$ (785) (13) 3,180
Selling, marketing and admin expenses 2,789 2,789
Research and development expense 2,869 2,869
Other segment items 14 69 (207) 8 (13) (129)
Adjusted Income Before Tax by Segment 5,552 785 (69) - 220 (8) - 13 6,493
MedTech
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 3,638	$ (482) (15) 1 3,142
Selling, marketing and admin expenses 2,862 2,862
Research and development expense 647 43 690
Other segment items 190 (83) (64) (53) (29) (14) (53)
Adjusted Income Before Tax by Segment 1,204 482 83 79 9 29 - 14 1,900
Expenses not allocated to segments
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 12	$ 12
Selling, marketing and admin expenses 238 238
Research and development expense - -
Other segment items 15 (43) (17) (45)
Adjusted Income Before Tax by Segment (265) - 43 - 17 - - - (205)
Johnson & Johnson Consolidated
Second Quarter
June 29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Second Quarter
June 29, 2025
Non-GAAP
Cost of products sold 7,628	$ (1,267) (15) (12) 6,334
Selling, marketing and admin expenses 5,889 5,889
Research and development expense 3,516 43 3,559
Other (Income) / Expense 107 (57) (277) (21) (27) (275)
In-process research and development impairments - -
Interest (Income)/Expense 48 48
Restructuring 64 (64) -
Adjusted Income Before Tax 6,491 1,267 57 79 246 21 - 27 8,188
Provision for taxes on income 954 222 9 13 72 5 214 - 1,489
Net Earnings 5,537	$ 1,045 48 66 174 16 (214) 27 6,699
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 15 of 17 --

Year to Date
Innovative Medicine
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 8,686	$ (1,527) (18) (19) 7,122
Selling, marketing and admin expenses 6,048 6,048
Research and development expense 5,688 5,688
Other segment items (178) 51 (182) (100) 282 (127)
Adjusted Income Before Tax by Segment 11,566 1,527 (51) - 200 119 (282) - - 13,079
MedTech
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 7,438	$ (965) (42) (3) 6,428
Selling, marketing and admin expenses 5,975 (17) 5,958
Research and development expense 1,492 (2) 1,490
Other segment items 241 117 (36) (96) (64) (10) (355) (203)
Adjusted Income Before Tax by Segment 2,416 965 (117) 36 138 64 10 377 - 3,889
Expenses not allocated to segments
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 33	$ 33
Selling, marketing and admin expenses 443 443
Research and development expense - -
Other segment items 769 (765) 7 11
Adjusted Income Before Tax by Segment (1,245) - 765 - - (7) - - - (487)
Johnson & Johnson Consolidated
Six Months June
28, 2026
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation Related
Tax legislation
and other tax
related
Six Months June
28, 2026
Non-GAAP
Cost of products sold 16,157	$ (2,492) (60) (19) (3) 13,583
Selling, marketing and admin expenses 12,466 (17) 12,449
Research and development expense 7,180 (2) 7,178
Other (Income) / Expense 625 (597) (212) (157) 272 (355) (424)
In-process research and development impairments 36 (36) -
Interest (Income)/Expense 105 105
Restructuring 66 (66) -
Adjusted Income Before Tax 12,737 2,492 597 36 338 176 (272) 377 - 16,481
Provision for taxes on income 1,968 479 131 8 124 45 (63) 68 26 2,786
Net Earnings 10,769	$ 2,013 466 28 214 131 (209) 309 (26) 13,695
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 16 of 17 --

Year to Date
Innovative Medicine
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 7,998	$ (1,434) (13) 6,551
Selling, marketing and admin expenses 5,050 5,050
Research and development expense 5,417 5,417
Other segment items (152) - 69 (227) (10) (13) (333)
Adjusted Income Before Tax by Segment 10,762 1,434 (69) - 240 10 - 13 12,390
MedTech
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 6,964	$ (953) (23) (51) 5,937
Selling, marketing and admin expenses 5,518 5,518
Research and development expense 1,324 37 1,361
Other segment items 130 (83) (111) (107) (50) (14) (235)
Adjusted Income Before Tax by Segment 2,625 953 83 134 121 50 - 14 3,980
Expenses not allocated to segments
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 23	$ 23
Selling, marketing and admin expenses 433 433
Research and development expense - -
Other segment items (7,191) 6,923 (17) (285)
Adjusted Income Before Tax by Segment 6,735 - (6,923) - 17 - - - (171)
Johnson & Johnson Consolidated
Six Months June
29, 2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related Other
Six Months June
29, 2025
Non-GAAP
Cost of products sold 14,985	$ (2,387) (23) (64) 12,511
Selling, marketing and admin expenses 11,001 11,001
Research and development expense 6,741 37 6,778
Other (Income) / Expense (7,214) 6,909 (30) (351) (60) (27) (773)
In-process research and development impairments - -
Interest (Income)/Expense (80) (80)
Restructuring 81 (81) -
Adjusted Income Before Tax 20,122 2,387 (6,909) 134 378 60 - 27 16,199
Provision for taxes on income 3,586 410 (1,544) 24 102 14 202 2,794
Net Earnings 16,536	$ 1,977 (5,365) 110 276 46 (202) 27 13,405
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 17 of 17 --